Intellectus Partners LLC Has $281,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Intellectus Partners LLC raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,131 shares of the company’s stock after purchasing an additional 250 shares during the quarter. Intellectus Partners LLC’s holdings in CRISPR Therapeutics were worth $281,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of CRSP. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics in the fourth quarter valued at approximately $39,000. Western Pacific Wealth Management LP raised its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after acquiring an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $40,000. Darwin Wealth Management LLC bought a new position in shares of CRISPR Therapeutics in the third quarter valued at approximately $43,000. Finally, Spire Wealth Management raised its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after acquiring an additional 1,482 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. The Goldman Sachs Group cut their target price on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Bank of America dropped their price objective on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. Barclays boosted their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $73.11.

CRISPR Therapeutics Stock Performance

CRSP opened at $45.53 on Friday. CRISPR Therapeutics AG has a 52 week low of $36.52 and a 52 week high of $81.73. The firm has a market capitalization of $3.91 billion, a PE ratio of -10.42 and a beta of 1.77. The company has a fifty day moving average price of $42.79 and a two-hundred day moving average price of $45.77.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Activity

In other news, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Greene purchased 7,000 shares of the firm’s stock in a transaction dated Wednesday, February 26th. The stock was purchased at an average cost of $44.85 per share, with a total value of $313,950.00. Following the acquisition, the director now directly owns 7,000 shares in the company, valued at $313,950. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 4.10% of the stock is owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.